Background: Gemcitabine is a deoxycytidine analog, which is used as first-line agent for pancreatic cancer therapy, and its efficacy relied on its intracellular conversion to active triphosphate form. However, administration with gemcitabine still has limited effect on the overall survival of patients with pancreatic cancer. Objective: We aimed to study the combination effect of gemcitabine and doxorubicin to pancreatic cancer cells BxPC3 and PANC1, and unveil the mechanism. Methods: The study was performed in pancreatic cancer cells PANC1 and BxPC3, the contribution of UMP/CMP kinase 1 (CMPK1) to gemcitabine in PANC1 and BxPC3 cells was measured by transfection of CMPK1 plasmid or CMPK1 siRNA treatment to adjust the expression of CMPK1 in the cells; then analyzed the cell vitality and migration after treated with 1% IC 50 of doxorubicin and gemcitabine or only with gemcitabine; the activity of CMPK1 and the effect of doxorubicin to the reaction was measured by HPLC assay in vitro; at last, docking analysis by computer was used to calculate the possible interaction sites of CMPK1 to DOX. Results: The sensitivity of PANC1 and BxPC3 cells to gemcitabine was improved when increasing the expression of CMPK1, and decreased when knockout CMPK1 by CMPK1 siRNA in BxPC3 cells; when combined with doxorubicin, the sensitivity of PANC1 and BxPC3 cells to gemcitabine also increased, and the cells migration reduced; we further found out that by adding 10 μM doxorubicin, the catalyzing activity of CMPK1 elevated about 2 times in vitro; the docking result showed that the association of CMPK1 to DOX was mainly by hydrogen bond and ionic interaction. Conclusion: CMPK1 can catalyze gemcitabine to its active form within the cells so that the sensitivity of the cells to gemcitabine elevated, and doxorubicin may enhance the cytotoxic effect to pancreatic cancer by up-regulate the activity of CMPK1, the combination of these deoxycytidine analogs with DOX might exert better efficacy.
Introduction
Pancreatic cancer is fatal for patients with a median survival of less than 6 months [1] , and has become one of the most devastating and deadly forms of cancers, and has an aggressive course predominantly seen in men at advanced age (40 -85 years) [2] . The highest incidence and mortality rates of pancreatic cancer are found in developed countries. Although the immune system [3] is considered to play an important role in the development and progression of pancreatic cancer, and many risk factors have also been identified, such as genetics, obesity, smoking, diabetes, inactivity [4] , the causes of pancreatic cancer are still insufficiently known. Curative surgery is nearly impossible because of its highly aggressive locoregional invasion [5] , and the treatments focusing on pancreatic cancer cells alone have failed to significantly improve patient outcome over many decades, more effective treatments are desperately needed.
Gemcitabine (2', 2'-difluorodeoxycytidine) has emerged as the first line treatment of pancreatic cancers. Gemcitabine belongs to pyrimidine analogs, which require stepwise phosphorylation to the respective triphosphate metabolites to exert their pharmacological activity: gemcitabine is phosphorylated to its monophosphate (dFdCMP) form by the deoxycytidine kinase (DCK), CMPK1 converts it to the active diphosphate form (dFdCDP), other nucleoside kinases further phosphorylate dFdCDP to its another active triphosphate (dFdCTP) forms [6] . Deoxyribonucleoside triphosphates are critical for DNA and RNA synthesis.
The importance of nucleoside analogs in the inhibition of viral replication and treatment of cancer has been recognized [7] . However, efficacy of gemcitabine for advanced and metastatic pancreatic cancer is limited. After injection, gemcitabine is often confronted with poor phosphorylation to its active triphosphate metabolite [1] .
CMPK1 is thought to play a major role in the activation of gemcitabine and its cytotoxicity, and is a rate limiting enzyme in the conversion of gemcitabine to triphosphate form in the cell [8] [9] . CMPK1 is part of pyrimidine nucleotide interconversion pathway, which catalyzes the phosphoryl transfer from adenosine-5'-triphosphate (ATP) to cytidine 5'-monophoaphate (CMP), 2'-deoxy-CMP (dCMP), uridine 5'-monophosphate (UMP) or other pyrimidine nucleotide analogs [10] . Many of these analogs are important anticancer and antiviral agents include gemcitabine. Furthermore, β-L-dioxaolanetibine (L-OddC) and [13] . The subcellular localization of CMPK1 has been found to be important for cancer progress which may be related to dysregulation of ECM and cell cycle molecules [14] . CMPK1 has also been identified as a prognostic marker for lymph-node negative (LNN) [15] and adjuvant systemic chemotherapy naive (ASCN) triple negative breast cancer (TNBC) patients [16] . Doxorubicin (DOX) is an anthracycline with complicated structure. Science it used as clinical agent in 1970s, doxorubicin has shown potential activity in anti-cancer therapy [17] . The mechanism of DOX was controversial. It is still broadly investigated by many research groups including ours [18] [19] . In our former work, we have screened the targets of DOX by high density protein array which contains 17,950 kinds of proteins [20] . We have first found out that CMPK1 was one of its targets, and DOX showed positive activation of CMPK1
in the phosphorylation of pyrimidine analogs from monophosphates to their diphosphate metabolites in vitro.
In this article, we aimed to investigate the contribution of CMPK1 to gemcitabine, and the contribution of DOX to CMPK1 dependent gemcitabine treatment. Knowing the relationship of gemcitabine, DOX and CMPK1 would guide pyrimidine analogs treatment to pancreatic cancer as well as other carcinomas.
Materials and Methods

Materials
The pancreatic cancer cells BxPC3 and PANC1 were gifts from Suzhou university school of medicine (Suzhou, China); Gemcitabine was purchased from Aladdin (Shanghai, China); Doxorubicin was purchased from Meilun (Dalian, China); Cell vitality assay kit was a product of Promega (America); DDK (DYKDDDDK) and CMPK1 antibody were gifts from Origene Technology (America); CMPK1 siRNA was a product of Santa Cruze (America); transfection reagent lipofectamine 2000 and opti-MEM medium were products of Invitrogen (America); CMPK1 protein was a product of Sino Biological (Beijing, China);
CMP&CDP&CTP HPLC standard was a product of Sigma (America).
Cell Culture and Growth Inhibition Assay
BxPC3 and PANC1 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, and maintained at 37˚C, 5% CO 2 with saturated humidity. 
CMPK1 siRNA Treatment
Western Blotting
For western blot analysis, cells were lysed with RIPA (20 mM PBS at pH 7.5, 300
mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 1% PMSF) in ice for 10 min, then centrifuged in 12,000 g, 4˚C for 10 min. The supernatant was tested by electrophoresis and immune-blot with primary antibodies and respective second antibodies. Chemiluminescence detection was done through a CCD camera using the ChemiDoc System (Bio-Rad) with Image Lab software (Bio-Rad, version 4.0).
Cell Migration Assay
The cells were collected by standard trypsinization when they grow to exponen- 
CMPK1 Activity Assay by HPLC
The assay of CMPK1 activity was performed in 300 μL of 50 mM Tris-acetate, 
Docking Analysis
Down load the crystal structure of CMPK1 (PDB ID:1TEV) and 3-D structure of DOX from PDB and PUMchem. Prepare protein and small molecular by Discovery studio 3.5 (DS), respectively. And use the tool of DS Find Sites to find out the possible association site of CMPK1 and DOX.
Statistical Analysis
Data was calculated by GraphPad Prism 6.0, Comparison of numerical data was done by using student t-test, The P value was considered significant if it was less than 0.05.
Results
The Activity of Gemcitabine Was Regulated by CMPK1
BxPC3 and PANC1 cells were transfected with CMPK1 plasmid which contained DKKDDDDK (DDK) tail. After transfection, the growth inhibition of gemcitabine to the cells was analyzed. Both BxPC3 and PANC1 cells expressed extra CMPK1 and showed increased sensitivity to gemcitabine (Figure 1(a) and Figure 1(b) ). 
Vitality(%)
We decreased the CMPK1 by CMPK1 siRNA in BxPC3 for its IC 50 was relatively low, the IC 50 of BxPC3 to gemcibatine increased responded to the decreased expression of CMPK1 in the cells (Figure 2 ).
Gemcitabine and Doxorubicin Combination Enhanced the Cytotoxic Effect to Pancreatic Cancer Cells BxPC3 and PANC1
BxPC3 and PANC1 cells were treated with 1% IC 50 of DOX and serially diluted gemcitabine, cells only treated with gemcitabine were set as control. BxPC3 and PANC1 cells both showed decreased IC 50 of gemcitabine (Figure 3(a) and Figure 3(b) ) with significant differences (Figure 3(c) ). With ADM
Control
Gemcitabine 0 μg/mL 1 μg/mL 2 μg/mL 5 μg/mL in vivo, and showed activity in aggressive renal tumors [22] . Many trials have been showed the advantages of such combination, but less explanations of the phenomenon, we unveiled one mechanism in this paper for better understanding.
On the other hand, we concluded that for most pyrimidine analogs, not just gemcitabine, the combination of these drugs with DOX may also showed great effect for they can be activated by CMPK1 through the association with DOX.
Conclusion
Dox combination with pyrimidine analogs may be more efficient for the activation effect of CMPK1 in cells and can be elevated by the association of CMPK1
and doxorubicin.
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